Blueprint Medicines
166 articles about Blueprint Medicines
-
Blueprint Medicines to Report First Quarter 2020 Financial Results on Wednesday, May 6, 2020
4/29/2020
Blueprint Medicines Corporation announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 6, 2020 to report its first quarter 2020 financial results and provide a corporate update.
-
Blueprint Medicines Announces Top-line Results from Phase 3 VOYAGER Trial of Avapritinib versus Regorafenib in Patients with Advanced Gastrointestinal Stromal Tumor
4/28/2020
VOYAGER did not meet the primary endpoint of an improvement in progression-free survival for avapritinib versus regorafenib in patients with third- or fourth-line GIST
-
This Clinical Catch-Up has been split into three sections: COVID-19-Related Clinical Trials; Non-COVID-19-Related Clinical Trials; and Trials Affected by the COVID-19 Pandemic. Here’s a look.
-
Blueprint Medicines Announces Part 1 Results from PIONEER Trial Showing Broad Activity of Avapritinib Across Measures of Mast Cell Burden, Clinical Outcomes and Quality of Life in Indolent Systemic Mastocytosis
3/16/2020
Blueprint Medicines Corporation today announced updated results from the Phase 2 pioneer trial.
-
Blueprint Medicines to Present at Upcoming Investor Conferences - Feb. 19, 2020
2/19/2020
Blueprint Medicines Corporation announced its participation in fireside chats at the following upcoming investor conferences
-
Blueprint Medicines to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 13, 2020
2/6/2020
Blueprint Medicines Corporation announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, February 13, 2020 to report its fourth quarter and full year 2019 financial results and provide a corporate update.
-
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
-
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock at $69.00 per share
1/23/2020
Blueprint Medicines Corporation announced the pricing of an underwritten public offering of 4,710,144 shares of its common stock at a public offering price of $69.00 per share, before underwriting discounts and commissions.
-
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock - Jan. 21, 2020
1/21/2020
Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, announced that it has commenced an underwritten public offering of $325,000,000 in shares of its common stock.
-
Blueprint Medicines Announces 2020 Corporate Goals
1/13/2020
Blueprint Medicines Corporation announced corporate goals for 2020, which provide a path to achieve the company's "2020 Blueprint" strategy for launching its global commercial business.
-
Late Thursday, the U.S. Food and Drug Administration approved a new therapy to treat a rare mutation in patients with gastrointestinal stromal tumors.
-
Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested
12/8/2019
Plan to initiate screening in registration-enabling portion of PIONEER trial in indolent SM in first half 2020
-
Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition
11/6/2019
Blueprint Medicines to Host Investor Event and Webcast on Sunday, December 8, 2019
-
Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results
11/5/2019
R&D Day presentation discloses four research programs demonstrating the transformative science, urgency and efficiency underpinning the company's integrated precision medicine platform
-
Blueprint Medicines to Host R&D Day and Announce Third Quarter 2019 Financial Results on November 5, 2019
10/29/2019
Blueprint Medicines Corporation announced that it will host a Research and Development Day for analysts and investors on Tuesday, November 5, 2019 beginning at 8:30 a.m. ET in New York City.
-
Ipsen and Blueprint Medicines Announce Exclusive Global License Agreement to Develop and Commercialize BLU-782 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
10/16/2019
Expands Ipsen’s Rare Diseases portfolio to include BLU-782, a highly selective investigational ALK2 inhibitor for the treatment of FOP
-
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
8/7/2019
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for avapritinib
-
Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference
8/6/2019
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that Andy Boral, M.D., Ph.D., Blueprint Medicines' Chief Medical Officer, will present a company overview at the 2019 Wedbush PacGrow Healthcare Conference in New York,
-
Blueprint Medicines Reports Second Quarter 2019 Financial Results
8/1/2019
Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, reported financial results and provided a business update for the quarter ended June 30, 2019.
-
Blueprint Medicines to Present at Upcoming Investor Conferences in June - May 29, 2019
5/29/2019
Blueprint Medicines Corporation announced its participation in the following upcoming investor conferences